Prevention of the Complications of Bleeding Disorder Through HTCs
通过 HTC 预防出血性疾病并发症
基本信息
- 批准号:7232169
- 负责人:
- 金额:$ 56.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-30 至 2011-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The purpose of this program is to prevent complications of hemophilia and other bleeding disorders through assessment, surveillance, outreach, education, consultation, and management. A regional network of ten hemophilia treatment centers in Kentucky, North Carolina, South Carolina, and Tennessee will be coordinated by the University of North Carolina at Chapel Hill and provide comprehensive care and prevention services to persons with hemophilia and other bleeding disorders. In 2005, Region IV-North (comprising nine hemophilia treatment centers [HTCs] in North Carolina, South Carolina, Kentucky, and Tennessee) had a total of 1,848 active patients with hemophilia and other bleeding disorders. Hemophilia patients constitute 61.5% of the total patients, while 27.6% have von Willebrand disease and 10.9% have other bleeding disorders. In 2005, there were 380 active female patients, an increase of 25.2% over the 2004 total. Almost 22% of the active patients are from ethnic minority groups, with an explosive increase in Hispanics. In comparison to U.S. averages, there are higher poverty rates and lower educational levels within the region, predisposing individuals to suboptimal behaviors in relation to diet, exercise, and use of health care services. The network will collaborate with regional lay organizations and the four non-federally funded centers in the region to deliver appropriately tailored prevention messages aimed at reducing complications of bleeding disorders and improving health across the lifespan, with the intention of attaining and measuring specific outcomes to reduce complications. Further, the region will redouble its outreach to underserved populations, such as women and minorities, to integrate them into the HTC system. All of these efforts will be systematically evaluated to assess their efficacy. Surveillance of patients enrolled in the CDC's Universal Data Collection (UDC) project, which has collected samples and data from over 18,000 individuals nationally since 1998, will continue in order to monitor the safety of the blood supply. The network will also expand upon the UDC program to collect data that could be used for clinical research projects leading to improved health outcomes for individuals with bleeding disorders, accelerated adoption of healthy behaviors, the reduction or elimination of health disparities among various ethnic and racial groups and between genders, and the achievement of greater efficiency in the core public health infrastructure.
描述(由申请人提供):该项目的目的是通过评估、监测、外展、教育、咨询和管理来预防血友病和其他出血性疾病的并发症。查佩尔山的北卡罗来纳州将协调肯塔基州、北卡罗来纳州、南卡罗来纳州和田纳西州的10个血友病治疗中心的区域网络,为血友病和其他出血性疾病患者提供全面的护理和预防服务。2005年,IV区-北部(包括北卡罗来纳州、南卡罗来纳州、肯塔基州和田纳西州的9个血友病治疗中心[HTC])共有1,848例血友病和其他出血性疾病患者。血友病患者占总患者的61.5%,而27.6%患有血管性血友病,10.9%患有其他出血性疾病。2005年,有380名女病人在接受治疗,比2004年的总数增加了25.2%。近22%的活跃患者来自少数民族群体,西班牙裔患者呈爆炸性增长。与美国的平均水平相比,该地区的贫困率较高,教育水平较低,使个人在饮食,运动和使用医疗保健服务方面倾向于次优行为。该网络将与该地区的非专业组织和四个非联邦资助的中心合作,提供适当的预防信息,旨在减少出血性疾病的并发症,改善整个生命周期的健康状况,旨在实现和衡量减少并发症的具体成果。此外,该区域将加倍努力,向妇女和少数民族等得不到充分服务的人口开展外联活动,将他们纳入人道主义援助系统。将对所有这些努力进行系统评价,以评估其效力。自1998年以来,疾病预防控制中心的通用数据收集(UDC)项目已收集了全国18,000多人的样本和数据,将继续监测患者,以监测血液供应的安全性。该网络还将扩大UDC计划,以收集可用于临床研究项目的数据,从而改善出血性疾病患者的健康状况,加速健康行为的采用,减少或消除各民族和种族群体之间以及性别之间的健康差异,并提高核心公共卫生基础设施的效率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul E Monahan其他文献
Paul E Monahan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul E Monahan', 18)}}的其他基金
Prevention of the Complications of Bleeding Disorder Through HTCs
通过 HTC 预防出血性疾病并发症
- 批准号:
7279179 - 财政年份:2006
- 资助金额:
$ 56.82万 - 项目类别:
Prevention of the Complications of Bleeding Disorder Through HTCs
通过 HTC 预防出血性疾病并发症
- 批准号:
7895782 - 财政年份:2006
- 资助金额:
$ 56.82万 - 项目类别:
Prevention of the Complications of Bleeding Disorder Through HTCs
通过 HTC 预防出血性疾病并发症
- 批准号:
7487521 - 财政年份:2006
- 资助金额:
$ 56.82万 - 项目类别:
Prevention of the Complications of Bleeding Disorder Through HTCs
通过 HTC 预防出血性疾病并发症
- 批准号:
7679721 - 财政年份:2006
- 资助金额:
$ 56.82万 - 项目类别:
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B
AAV 定向肌肉基因治疗 B 型血友病
- 批准号:
6476709 - 财政年份:1999
- 资助金额:
$ 56.82万 - 项目类别:
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B
AAV 定向肌肉基因治疗 B 型血友病
- 批准号:
2738471 - 财政年份:1999
- 资助金额:
$ 56.82万 - 项目类别:
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B
AAV 定向肌肉基因治疗 B 型血友病
- 批准号:
6625215 - 财政年份:1999
- 资助金额:
$ 56.82万 - 项目类别:
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B
AAV 定向肌肉基因治疗 B 型血友病
- 批准号:
6125669 - 财政年份:1999
- 资助金额:
$ 56.82万 - 项目类别:
AAV DIRECTED MUSCLE GENE THERAPY FOR HEMOPHILIA B
AAV 定向肌肉基因治疗 B 型血友病
- 批准号:
6329989 - 财政年份:1999
- 资助金额:
$ 56.82万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 56.82万 - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 56.82万 - 项目类别:














{{item.name}}会员




